Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
(00:00):
Welcome to the public Affairs show ofyour favorite local iHeartRadio station in Seattle.
I'm your host, Lee Callahan.Got two great guests on the phone with
me today from two different local organizationsworking together, partnering to make life better
for all of us. From OzetteTechnologies, I have Sharie Green, she
is the vice president of Translational Scienceat Osette. And from blood Works Bio,
(00:25):
part of Blood Work's Northwest, I'vegot executive vice president Aaron Posey.
I'll start with Aaron. We're allfamiliar with Blood Works Northwest. I've had
your CEO on many times to talkabout blood donation and how critical that is.
But blood Works Bio is a portionof what Blood Works Northwest does.
(00:45):
Will you tell us about that?Definitely? Yes. I'm Aaron Posey,
the executive vice president of Bloodworks Bio. We are a department within Blood Works
and we provide starting material to cellulare gene therapy organizations to fuel their pipeline
of drug development. And so whatdoes that actually mean? So we provide
(01:11):
different types of blood products, youknow, very similar to the main operations
of Blood Works Northwest, where wesupply healthy blood for transfusion. We also
start with blood, but we takeit to a different level, if you
will. We can remove from bloodeither at the whole blood or blood derived
(01:37):
from a process known as aphoresis.We can remove specialized cells per the specifications
of our sellingen therapy customers. Wecan then enrich those cells or make them
a homogeneous population to provide to thesell enging therapy companies that they use in
their platforms for generating sellinging therapy drugsor or you know, oh gosh,
(02:06):
how would I put that pharmaceutical medication? Yeah, you got it, yes,
yes, pharmacy, yeah, selgene therapies across you know, many
different ailments including you know, cancer, autoimmune disease, et cetera. Wow,
okay, this is good information.Many questions are a bruin already.
(02:28):
I have got Sharie Green. Sheis from Oseet Technologies. Would you tell
me about what oset does? You'reright here in Seattle, absolutely so.
Yeah. We Osette is a startupcompany that was founded in the heart of
the Pacific Northwest and Seattle. Andour technology really focuses on UH innovative approaches
(02:57):
to profile single cells, so theimmune system, what kind of cells are
in our body? UH? AndOur technology originated from the Fred Hatch Cancer
Center with leaders in the field ofcomputational science UH and our founders include Greg
Finnak, Raphael Guitardo, and EvanGreen. And so what we've done is
(03:23):
we've spun out a company UH toreally focus on using state of the art
technologies such as glowsitometry and RNA sequencingand machine learning algorithms to analyze the data
with the mission of understanding the immunesystem, both in health and disease.
(03:43):
And really our goal is to youknow, deeply profile and understand the immune
system to accelerate new developments of therapiesfor a myriad of diseases. Interesting,
would you say a lot of whatyou're looking at in the as far as
(04:05):
diseases go or autoimmune or is itjust everything? Well, I mean,
you know, immune cells are youknow, the foundation of our body and
they can be in a health stateor in a disease state. So you
know, this is true for autoimmunewhere our immune cells aren't functioning properly,
and also in the case of oncologywhere you have you know, cancer cells
(04:29):
that overtake our normal or our healthyimmune system. And so we really focus
on all the cells in the bodyacross many different diseases, including infectious disease,
oncology, and autoimmune diseases. Fascinating. I have got Aaron post that's
chery Green from Osette. Aaron Poseyis on the line also from blood Works
(04:56):
Bio Aaron, why will you tellme why you two need need each other
in this partnership? Absolutely, Ithink it's actually multifaceted. You know,
when we did the ideation phase ofthese projects, we came up with a
number of different ways to think aboutAI or artificial intelligence to help us solve
(05:19):
things that we cannot solve in alaboratory setting. So it's kind of peeling
back the onion to really look atother methods that provide the answers to problems
that we can't generally solve just bydoing laboratory or benchwork in a laboratory setting.
(05:40):
Okay, next, you mentioned aesis. The apharesis model can be used
for either therapeutic reasons. So whenpeople need a plasma exchange, they will
undergo in aphoresi's treatment for that.You can also derive plasma from an aphoresis
model for recovered plasma for fractionation.You know, they could also be used
(06:04):
for a growth factor within cellular culture. But what we're really focusing on is
really the cellular components that you getout of an aphoresis process in abundance where
you can't get them from a typicalblood drop. Okay, this is where
the public comes in because you stillneed donors for this work that you are
(06:28):
doing with those z labs. AmI right? That is correct? Yes,
the donors are the basis for whatwe do. Without donors or without
specific donor recruitment tactics, we wouldn'thave a business. So every client that
comes to us that is the needof a leucophoresis which is derived from the
(06:49):
process of apharesis, we have togo through a very specialized recruitment of not
only identifying the donor, screening isa donor or infectious disease markers or you
know, whatever specification the client hasasked us to screen for, and and
(07:10):
then we have to do a vanassessment to make sure that they're suitable for
the aphoris procedure. So it's it'squite a commitment from a donor to take
time out of their day to comein and go through a three to four
to maybe sometimes five hour procedure.Uh, so that we can provide the
(07:31):
correct material to the seal gene therapycompanies that are generating cell gene therapies.
Oh wow, that's a lot longerthan it took me. Yeah, there,
there's there's a there's quite a fewdifferent methods for apheresis, a lot
of which we're evaluating with OSETTE.So the most basic is a leucopharesis collection.
(07:57):
That's typically around a three hour process. And basic, as you had
mentioned, your blood is taken fromyour body. It is put through a
machine and the centrivigation process where we'veremoved the components that we're looking for in
this case pdmcs or peripheral blood mononuclearsites, and then everything else is returned
(08:20):
back to your body, including theplasma of the serum with a little bit
of additive plasma or serum into theleucofrequs pact. But you retain all of
the other types of cells. Yourred blood cells go back in most of
your plasma, most of your serum, and then your body will regenerate those
(08:41):
cell types over time, and soit's a very regulated process. Green is
on the phone with me also.That was Aaron Posey from blood Works Bio
an arm of Blood Works Northwest.Chari green Is from Ozette Cherie. If
you could encapsulate talking to a donor, what would you say that might just
(09:03):
push them into coming in for threeor four hours? You know, what
would you say if you If youdo this, then this is gonna happen.
Yeah, I mean, I thinkit's pretty critical for donors to come
in and volunteer their time and theirprecious biological materials. It's just in a
lot of different ways. One additionalso we've we've been talking about to say
(09:28):
faresis there is also, you know, a process in which you can enrich
specific cells that are important in UHlet's say UH transplantation. So patients,
cancer patients go through stem cell transplantationUH, and so there are certain types
(09:50):
of cells within that aphoresis that canbe mobilized through the administration of growth factors.
And one thing that Aaron and Iare are doing together is trying to
predict what types of UH native cellsor a composition of cells in the body
(10:13):
could predict a better mobilized donor.So UH stem cells are are kind of
the beginning UH path of our hematopoesisuh and important in regenerating cells in the
body, and so you can infusestem cells back into a patient for for
(10:37):
treatment. And what our technology doesis it actually profiles all the cells that
come out of a product, whetherit's whole blood, apheresis, mobilized blood.
What's a really powerful component of ourcollaboration is that, you know,
blood Works provides these very important bloodproducts for you know, for patients and
(11:03):
for drug development companies. UH.These products are also like the starting material
for cell therapy products. So I'msure you've heard in the news about you
know, car tis. These arespecific kind of cell therapy and you can
use T cells from the patient orfrom donors and that's called an alo car
(11:26):
tee. And the material that isgenerated that Bloodworks bio is actually the beginning
material. And without understanding what theimmune profile is of the cells that are
going into that starting materials kind ofan unknown. So that's that's where we're
excited about collaborating. I'm just gonnabreak it down. So you know,
(11:48):
when we talk about uh, cellulartherapy, celluo therapy can be anything from
you know taking uh, you know, stem cells and doing at transplants that's
like, you know, that's beenaround for many, many decades, but
in the last you know, tenyears, car key products, which are
(12:11):
chimeric antigen receptor key cells, Sothey're taking cells from either a healthy donor
or the cancer patient and they're modifyingthem in some way to be killing machines.
So they are potent therapy to targetcancer cells in the body and have
(12:33):
had pretty sizable responses in certain populationsof cancer. And so these are all
originating from blood products, either fromthe patient or from healthy donors from blood
works bio. I've also got AaronPosey, what were you going to add
to that? Erin No, Imean, Saria is exactly right. And
(12:56):
you know we support all those clinicaltrials with a lot of different organizations that
are developing the products from the startingmaterial. And you know, I kind
of want to focus on one ofthe outcomes of you know, using AI
and you know, using these youknow, pressure cells to uncover the secrets.
(13:18):
It really has a cost benefit,you know in the end, uh,
these are all very expensive procedures.And I'll talk about mobilized dapharesis first.
Okay, you know there's no guaranteeon how well a donor will mobilize,
and when I say mobilized, there'sno guarantee on how many stem cells
(13:39):
they generate within their bone marrow,and that are released is the perpheral blood,
which we then capture by aphoresis.So you know, when our clients
come to us and they have togo through this process, it's a very
expensive process to obtain the starting material, and you know, the end results
could mean that donor wasn't suitable formobilized dapheresis. So you know, not
(14:03):
only have we wasted that donor time, but we've also you know, now
passed the expense on to the clientto pay for that process. And so
by using AI to determine who wouldor who would not be a good candidate
for mobilized dapheresis, there's really acost savings in the end of all this
because you you would, you know, simply guarantee that well, the hope
(14:26):
is that you would guarantee that adonor would be able to mobilize well and
produce a high number of DEM cellsto then enrich and to be used in
the pre clinical or clinical settings.When it comes to what Sherry had alluded
to about, you know, specificallyisolating specific types of cells. One of
(14:50):
the projects that we're working on isthe isolation of the NK cell and really
looking at that or a natural killercell. It's also used uh uh uh
for therapeutic development, similarly as aT cell would be used, as Sherry
have alluded to for car tey uh. They program these cell types to be
(15:11):
killing machines. When I say killingmachines, they kill the cancers that are
uplicting you know, these these people, and you know, one of the
things is that we don't understand,you know, from a donor perspective,
what makes their cells act in away or behave in a way, or
have the characteristics for the manufacturing endof the therapeutic And this is a very
(15:37):
expensive process that's you know, hundredsof millions of dollars have been spent on
you know, generating you know,very specific manufacturing modalities and methods for these
different cell types. And so oneof the questions from a client perspective that
we're helped trying to help understand isyou know, how well these cells will
(16:00):
do in the manufacturing process, andhow well they'll proliferate or grow, and
how how well the body will receivethem once they're put back into a human
either from their own cells or froma donor other than themselves. Who wants
to talk about who you're looking forto become donors. At this level,
(16:25):
donor recruitment is very specialized. Soyou know, we often have very specific
criteria by which we have to recruitfrom a pool of donors, if you
will, and that could be basedoff of infectious disease markers, it could
be based off of very specific parametersincluding h L a type which generally indicates
(16:51):
how well somebody will receive that productfrom a different donor other than themselves.
So it has to be asked.You can recruit based off of ethnicity,
demographics, health history, you nameit. There's there's a there's a whole
(17:12):
array by which we get asked torecruit very specific donors. So the larger
the pool we have of donors,the more we have to choose from to
be able to you know, supplythese pressure cells to these seal engine therapy
companies that are generating products to savelives. If a person wants to be
(17:32):
tested to see if they can donatein this way, what are their first
steps? We have a website bloodworksbiodot org and you can there's there's a
syllable form within that website that wewould then contact you, uh and pre
(17:52):
screen you and if you qualify,then you would be inserted into our research
donor pool. Just to wrap thingsup, I just want to make sure
I'm not missing any more salient points. I just think this is a really
exciting way to use data to empoweryou know, the way that we work,
uh, and to empower you know, us to be you know,
(18:15):
very selective on you know who asa donor we choose to go through the
process, and it's really just unlockingthe power of data and correlating that data
back to you know, our operations. And so I think that there's a
lot of power there and you know, I'm sure sure we will will back
(18:37):
that up. And maybe she's gother own testament to that. Yeah,
I would say on the other side, we're just incredibly excited about this collaboration
because what it does is that itallows we we have built some very state
of the art technology to profile youknow, cells in the body, and
(18:59):
then with our machine learning approach,you know, really harnessing you know,
AI machine learning to find signals,you know, to to identify people who
can respond better, you know,all the things that we've talked about.
(19:19):
But it's to us, it's justa great opportunity and a local opportunity for
us to partner together to do somethingthat hasn't been done before, and so
it's exciting, it really is,and ultimately leading to saving lives, which
is just a beautiful thing. FromOzette Technologies Scharie Green. She is the
(19:41):
vice president of Translational Science at Ozetteand from blood Works Bio part of blood
Works Northwest. Executive vice president,Aaron Posey, I appreciate the two of
you so much being on the showtoday and for your collaboration and everybody,
if you want to get in onbecoming a donor, go through the process,
(20:03):
go to bloodworksbio dot org. Isthat right, Aaron? That is
correct. Thanks for your time,late, you bet, Thank you. Kay
Welcome to the public Affairs show ofyour favorite local iHeartRadio station in Seattle.
I'm your host, Lee Callahan.Got two great guests on the phone with
me today from two different local organizationsworking together, partnering to make life better
for all of us. From OzetteTechnologies, I have Sharie Green, she
is the vice president of Translational Scienceat Osette. And from blood Works Bio,
(00:25):
part of Blood Work's Northwest, I'vegot executive vice president Aaron Posey.
I'll start with Aaron. We're allfamiliar with Blood Works Northwest. I've had
your CEO on many times to talkabout blood donation and how critical that is.
But blood Works Bio is a portionof what Blood Works Northwest does.
(00:45):
Will you tell us about that?Definitely? Yes. I'm Aaron Posey,
the executive vice president of Bloodworks Bio. We are a department within Blood Works
and we provide starting material to cellulare gene therapy organizations to fuel their pipeline
of drug development. And so whatdoes that actually mean? So we provide
(01:11):
different types of blood products, youknow, very similar to the main operations
of Blood Works Northwest, where wesupply healthy blood for transfusion. We also
start with blood, but we takeit to a different level, if you
will. We can remove from bloodeither at the whole blood or blood derived
(01:37):
from a process known as aphoresis.We can remove specialized cells per the specifications
of our sellingen therapy customers. Wecan then enrich those cells or make them
a homogeneous population to provide to thesell enging therapy companies that they use in
their platforms for generating sellinging therapy drugsor or you know, oh gosh,
(02:06):
how would I put that pharmaceutical medication? Yeah, you got it, yes,
yes, pharmacy, yeah, selgene therapies across you know, many
different ailments including you know, cancer, autoimmune disease, et cetera. Wow,
okay, this is good information.Many questions are a bruin already.
(02:28):
I have got Sharie Green. Sheis from Oseet Technologies. Would you tell
me about what oset does? You'reright here in Seattle, absolutely so.
Yeah. We Osette is a startupcompany that was founded in the heart of
the Pacific Northwest and Seattle. Andour technology really focuses on UH innovative approaches
(02:57):
to profile single cells, so theimmune system, what kind of cells are
in our body? UH? AndOur technology originated from the Fred Hatch Cancer
Center with leaders in the field ofcomputational science UH and our founders include Greg
Finnak, Raphael Guitardo, and EvanGreen. And so what we've done is
(03:23):
we've spun out a company UH toreally focus on using state of the art
technologies such as glowsitometry and RNA sequencingand machine learning algorithms to analyze the data
with the mission of understanding the immunesystem, both in health and disease.
(03:43):
And really our goal is to youknow, deeply profile and understand the immune
system to accelerate new developments of therapiesfor a myriad of diseases. Interesting,
would you say a lot of whatyou're looking at in the as far as
(04:05):
diseases go or autoimmune or is itjust everything? Well, I mean,
you know, immune cells are youknow, the foundation of our body and
they can be in a health stateor in a disease state. So you
know, this is true for autoimmunewhere our immune cells aren't functioning properly,
and also in the case of oncologywhere you have you know, cancer cells
(04:29):
that overtake our normal or our healthyimmune system. And so we really focus
on all the cells in the bodyacross many different diseases, including infectious disease,
oncology, and autoimmune diseases. Fascinating. I have got Aaron post that's
chery Green from Osette. Aaron Poseyis on the line also from blood Works
(04:56):
Bio Aaron, why will you tellme why you two need need each other
in this partnership? Absolutely, Ithink it's actually multifaceted. You know,
when we did the ideation phase ofthese projects, we came up with a
number of different ways to think aboutAI or artificial intelligence to help us solve
(05:19):
things that we cannot solve in alaboratory setting. So it's kind of peeling
back the onion to really look atother methods that provide the answers to problems
that we can't generally solve just bydoing laboratory or benchwork in a laboratory setting.
(05:40):
Okay, next, you mentioned aesis. The apharesis model can be used
for either therapeutic reasons. So whenpeople need a plasma exchange, they will
undergo in aphoresi's treatment for that.You can also derive plasma from an aphoresis
model for recovered plasma for fractionation.You know, they could also be used
(06:04):
for a growth factor within cellular culture. But what we're really focusing on is
really the cellular components that you getout of an aphoresis process in abundance where
you can't get them from a typicalblood drop. Okay, this is where
the public comes in because you stillneed donors for this work that you are
(06:28):
doing with those z labs. AmI right? That is correct? Yes,
the donors are the basis for whatwe do. Without donors or without
specific donor recruitment tactics, we wouldn'thave a business. So every client that
comes to us that is the needof a leucophoresis which is derived from the
(06:49):
process of apharesis, we have togo through a very specialized recruitment of not
only identifying the donor, screening isa donor or infectious disease markers or you
know, whatever specification the client hasasked us to screen for, and and
(07:10):
then we have to do a vanassessment to make sure that they're suitable for
the aphoris procedure. So it's it'squite a commitment from a donor to take
time out of their day to comein and go through a three to four
to maybe sometimes five hour procedure.Uh, so that we can provide the
(07:31):
correct material to the seal gene therapycompanies that are generating cell gene therapies.
Oh wow, that's a lot longerthan it took me. Yeah, there,
there's there's a there's quite a fewdifferent methods for apheresis, a lot
of which we're evaluating with OSETTE.So the most basic is a leucopharesis collection.
(07:57):
That's typically around a three hour process. And basic, as you had
mentioned, your blood is taken fromyour body. It is put through a
machine and the centrivigation process where we'veremoved the components that we're looking for in
this case pdmcs or peripheral blood mononuclearsites, and then everything else is returned
(08:20):
back to your body, including theplasma of the serum with a little bit
of additive plasma or serum into theleucofrequs pact. But you retain all of
the other types of cells. Yourred blood cells go back in most of
your plasma, most of your serum, and then your body will regenerate those
(08:41):
cell types over time, and soit's a very regulated process. Green is
on the phone with me also.That was Aaron Posey from blood Works Bio
an arm of Blood Works Northwest.Chari green Is from Ozette Cherie. If
you could encapsulate talking to a donor, what would you say that might just
(09:03):
push them into coming in for threeor four hours? You know, what
would you say if you If youdo this, then this is gonna happen.
Yeah, I mean, I thinkit's pretty critical for donors to come
in and volunteer their time and theirprecious biological materials. It's just in a
lot of different ways. One additionalso we've we've been talking about to say
(09:28):
faresis there is also, you know, a process in which you can enrich
specific cells that are important in UHlet's say UH transplantation. So patients,
cancer patients go through stem cell transplantationUH, and so there are certain types
(09:50):
of cells within that aphoresis that canbe mobilized through the administration of growth factors.
And one thing that Aaron and Iare are doing together is trying to
predict what types of UH native cellsor a composition of cells in the body
(10:13):
could predict a better mobilized donor.So UH stem cells are are kind of
the beginning UH path of our hematopoesisuh and important in regenerating cells in the
body, and so you can infusestem cells back into a patient for for
(10:37):
treatment. And what our technology doesis it actually profiles all the cells that
come out of a product, whetherit's whole blood, apheresis, mobilized blood.
What's a really powerful component of ourcollaboration is that, you know,
blood Works provides these very important bloodproducts for you know, for patients and
(11:03):
for drug development companies. UH.These products are also like the starting material
for cell therapy products. So I'msure you've heard in the news about you
know, car tis. These arespecific kind of cell therapy and you can
use T cells from the patient orfrom donors and that's called an alo car
(11:26):
tee. And the material that isgenerated that Bloodworks bio is actually the beginning
material. And without understanding what theimmune profile is of the cells that are
going into that starting materials kind ofan unknown. So that's that's where we're
excited about collaborating. I'm just gonnabreak it down. So you know,
(11:48):
when we talk about uh, cellulartherapy, celluo therapy can be anything from
you know taking uh, you know, stem cells and doing at transplants that's
like, you know, that's beenaround for many, many decades, but
in the last you know, tenyears, car key products, which are
(12:11):
chimeric antigen receptor key cells, Sothey're taking cells from either a healthy donor
or the cancer patient and they're modifyingthem in some way to be killing machines.
So they are potent therapy to targetcancer cells in the body and have
(12:33):
had pretty sizable responses in certain populationsof cancer. And so these are all
originating from blood products, either fromthe patient or from healthy donors from blood
works bio. I've also got AaronPosey, what were you going to add
to that? Erin No, Imean, Saria is exactly right. And
(12:56):
you know we support all those clinicaltrials with a lot of different organizations that
are developing the products from the startingmaterial. And you know, I kind
of want to focus on one ofthe outcomes of you know, using AI
and you know, using these youknow, pressure cells to uncover the secrets.
(13:18):
It really has a cost benefit,you know in the end, uh,
these are all very expensive procedures.And I'll talk about mobilized dapharesis first.
Okay, you know there's no guaranteeon how well a donor will mobilize,
and when I say mobilized, there'sno guarantee on how many stem cells
(13:39):
they generate within their bone marrow,and that are released is the perpheral blood,
which we then capture by aphoresis.So you know, when our clients
come to us and they have togo through this process, it's a very
expensive process to obtain the starting material, and you know, the end results
could mean that donor wasn't suitable formobilized dapheresis. So you know, not
(14:03):
only have we wasted that donor time, but we've also you know, now
passed the expense on to the clientto pay for that process. And so
by using AI to determine who wouldor who would not be a good candidate
for mobilized dapheresis, there's really acost savings in the end of all this
because you you would, you know, simply guarantee that well, the hope
(14:26):
is that you would guarantee that adonor would be able to mobilize well and
produce a high number of DEM cellsto then enrich and to be used in
the pre clinical or clinical settings.When it comes to what Sherry had alluded
to about, you know, specificallyisolating specific types of cells. One of
(14:50):
the projects that we're working on isthe isolation of the NK cell and really
looking at that or a natural killercell. It's also used uh uh uh
for therapeutic development, similarly as aT cell would be used, as Sherry
have alluded to for car tey uh. They program these cell types to be
(15:11):
killing machines. When I say killingmachines, they kill the cancers that are
uplicting you know, these these people, and you know, one of the
things is that we don't understand,you know, from a donor perspective,
what makes their cells act in away or behave in a way, or
have the characteristics for the manufacturing endof the therapeutic And this is a very
(15:37):
expensive process that's you know, hundredsof millions of dollars have been spent on
you know, generating you know,very specific manufacturing modalities and methods for these
different cell types. And so oneof the questions from a client perspective that
we're helped trying to help understand isyou know, how well these cells will
(16:00):
do in the manufacturing process, andhow well they'll proliferate or grow, and
how how well the body will receivethem once they're put back into a human
either from their own cells or froma donor other than themselves. Who wants
to talk about who you're looking forto become donors. At this level,
(16:25):
donor recruitment is very specialized. Soyou know, we often have very specific
criteria by which we have to recruitfrom a pool of donors, if you
will, and that could be basedoff of infectious disease markers, it could
be based off of very specific parametersincluding h L a type which generally indicates
(16:51):
how well somebody will receive that productfrom a different donor other than themselves.
So it has to be asked.You can recruit based off of ethnicity,
demographics, health history, you nameit. There's there's a there's a whole
(17:12):
array by which we get asked torecruit very specific donors. So the larger
the pool we have of donors,the more we have to choose from to
be able to you know, supplythese pressure cells to these seal engine therapy
companies that are generating products to savelives. If a person wants to be
(17:32):
tested to see if they can donatein this way, what are their first
steps? We have a website bloodworksbiodot org and you can there's there's a
syllable form within that website that wewould then contact you, uh and pre
(17:52):
screen you and if you qualify,then you would be inserted into our research
donor pool. Just to wrap thingsup, I just want to make sure
I'm not missing any more salient points. I just think this is a really
exciting way to use data to empoweryou know, the way that we work,
uh, and to empower you know, us to be you know,
(18:15):
very selective on you know who asa donor we choose to go through the
process, and it's really just unlockingthe power of data and correlating that data
back to you know, our operations. And so I think that there's a
lot of power there and you know, I'm sure sure we will will back
(18:37):
that up. And maybe she's gother own testament to that. Yeah,
I would say on the other side, we're just incredibly excited about this collaboration
because what it does is that itallows we we have built some very state
of the art technology to profile youknow, cells in the body, and
(18:59):
then with our machine learning approach,you know, really harnessing you know,
AI machine learning to find signals,you know, to to identify people who
can respond better, you know,all the things that we've talked about.
(19:19):
But it's to us, it's justa great opportunity and a local opportunity for
us to partner together to do somethingthat hasn't been done before, and so
it's exciting, it really is,and ultimately leading to saving lives, which
is just a beautiful thing. FromOzette Technologies Scharie Green. She is the
(19:41):
vice president of Translational Science at Ozetteand from blood Works Bio part of blood
Works Northwest. Executive vice president,Aaron Posey, I appreciate the two of
you so much being on the showtoday and for your collaboration and everybody,
if you want to get in onbecoming a donor, go through the process,
(20:03):
go to bloodworksbio dot org. Isthat right, Aaron? That is
correct. Thanks for your time,late, you bet, Thank you. Kay
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!